Trial reportActa dermato-venereologica2026
Efficacy and Safety of Xeligekimab Compared to Other IL-17A Inhibitors for Chinese Patients with Moderate-to-severe Plaque Psoriasis: A Matching-adjusted Indirect Comparisons.
Trial report in Acta dermato-venereologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Direct comparative evidence between IL-17A inhibitors for plaque psoriasis in Chinese populations remains limited. This study evaluated the comparative effectiveness of Xeligekimab vs Secukinumab and Ixekizumab through matchingadjusted indirect comparisons (MAICs). Individual patient data from the Xeligekimab trial (N=281) were weighted to match baseline characteristics from Chinese trials of Secukinumab (N=221) and Ixekizumab (N=176/92). Matching variables were determined following NICE and EUnetHTA MAIC guidelines, incorporating prognostic factors identified through multivariate regression. Primary endpoints included PASI 75/90/100 achievement at weeks 12, 52 and 60. At week 12, Secukinumab showed numerically higher PASI 75 (97.7% vs 93.0%, p=0.052) without statistical significance, while other endpoints were comparable (all p>0.05). At week 52, Xeligekimab showed significantly higher PASI 100 achievement (57.8% vs 42.1%, p=0.005) and DLQI 0/1 (68.8% vs 47.5%, p<0.001) vs Secukinumab. At week 60, Xeligekimab maintained significantly higher PASI 75 vs Ixekizumab (92.6% vs 76.1%, p<0.001) with lower infection rates during induction period (7.9% vs 34.7%, p<0.001) and maintenance period (22.4% vs 56.5%, p<0.001). This MAIC provides hypothesis-enerating evidence that Xeligekimab may offer advantages in specific long-term efficacy endpoints and safety outcomes, requiring confirmation in direct randomized controlled trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.